Abstract
The current vaccine against TB, bacille Calmette-Guèrin (BCG) fails to protect against the most prevalent disease form, the pulmonary TB in adults. Thus, it is not a satisfactory vaccine.
Given that T cells are central to protection against TB, future vaccine design should focus on T-lymphocyte populations. Most vaccines do not prevent infection but instead disease, that if they allow establishment of the pathogen in the host but prevent its harmful effects.
The development of synthetic peptide-based immunogens is emerging as a possible approach in human vaccination in the future, as a replacement for conventional vaccines that use killed or attenuated whole microorganisms. The advantages of such synthetic vaccines (high potency, low adverse reactions, low cross-reactivity and high stability) are offset somewhat by the poorer inherent immunogenicity of these constructs. There is a greater need therefore to develop adjuvant/carrier systems to increase the immunogenicity of these newer vaccine candidates.
Keywords: Adjuvants, peptidic vaccine, proteomics, subunit approach, BCG, TB, tuberculosis.
Current Drug Targets
Title:Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Volume: 14 Issue: 9
Author(s): Adriano Mollica, Azzurra Stefanucci and Roberto Costante
Affiliation:
Keywords: Adjuvants, peptidic vaccine, proteomics, subunit approach, BCG, TB, tuberculosis.
Abstract: The current vaccine against TB, bacille Calmette-Guèrin (BCG) fails to protect against the most prevalent disease form, the pulmonary TB in adults. Thus, it is not a satisfactory vaccine.
Given that T cells are central to protection against TB, future vaccine design should focus on T-lymphocyte populations. Most vaccines do not prevent infection but instead disease, that if they allow establishment of the pathogen in the host but prevent its harmful effects.
The development of synthetic peptide-based immunogens is emerging as a possible approach in human vaccination in the future, as a replacement for conventional vaccines that use killed or attenuated whole microorganisms. The advantages of such synthetic vaccines (high potency, low adverse reactions, low cross-reactivity and high stability) are offset somewhat by the poorer inherent immunogenicity of these constructs. There is a greater need therefore to develop adjuvant/carrier systems to increase the immunogenicity of these newer vaccine candidates.
Export Options
About this article
Cite this article as:
Mollica Adriano, Stefanucci Azzurra and Costante Roberto, Strategies for Developing Tuberculosis Vaccines: Emerging Approaches, Current Drug Targets 2013; 14 (9) . https://dx.doi.org/10.2174/1389450111314090002
DOI https://dx.doi.org/10.2174/1389450111314090002 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Flavonoids from Cassia Species and their Biological Activity
Current Pharmaceutical Biotechnology T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Current Signal Transduction Therapy Pulmonary Vaccine Delivery Systems: A Novel Approach for Immunization
Current Drug Therapy Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Pyrazolines: A Biological Review
Mini-Reviews in Medicinal Chemistry Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals
Current Pharmaceutical Design Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Uveitis in Horses, Rats and Man: What Do We Learn from Our Pets?
Current Immunology Reviews (Discontinued) Editorial [Hot Topic: HIV Drug Design (Executive Editor: A.S. Bourinbaiar)]
Current Pharmaceutical Design Editorial
Current Drug Targets - Infectious Disorders Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase
Medicinal Chemistry Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Human Tuberculosis II. M. tuberculosis Mechanisms of Genetic and Phenotypic Resistance to Anti-Tuberculosis Drugs
Current Medicinal Chemistry Orchestration of Host-Pathogen Interaction: Relevance of Iron in Generation of Potent Anti-M. tuberculosis Immunity
Current Pharmaceutical Biotechnology Mycobacterium tuberculosis and Dendritic Cells: Whos Manipulating Whom?
Current Immunology Reviews (Discontinued) Appropriate Antibiotic Prescribing Pattern in Hospitalized Children
Current Drug Safety Spices Chemoconstituents as Persuasive Inhibitor of S. typhimurium Virulent Protein L-asparaginase
Letters in Drug Design & Discovery Synthesis and In Vitro Evaluation of Novel 1, 2, 4-Triazole Derivatives as Antifungal Agents
Letters in Drug Design & Discovery Thermostable Subunit Vaccines for Pulmonary Delivery: How Close Are We?
Current Pharmaceutical Design